Molecular complete remission (CR): Glitazones decrease expression of STAT5 and its downstream targets HIF2α and CITED2, which are key guardians of the quiescence and stemness of CML leukemia stem cells (LSCs). Here, EPAS1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.